Findings

What do systematic reviews say?

3,241 questions · 3,336 findings · 1,340 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,581 · 47.4%GRADE not reported 352 · 10.6%Very low 512 · 15.3%Low 509 · 15.3%Moderate 316 · 9.5%High 66 · 2%

Motivational interviewing vs control

Quality of life ‐ not measured · patients with Improving outcomes in youth living with HIV

The review found no eligible studies for this question.

1 finding from 1 review

Motivational interviewing for improving outcomes in youth living with HIV 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Health‐related quality of life · patients with LADA

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for latent autoimmune diabetes (LADA) in adults 2011 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Augmented subscapularis transposition vs subscapularis transposition alone during total shoulder arthroplasty

Quality of life ‐ not reported · Patients with rheumatoid shoulder

The review found no eligible studies for this question.

1 finding from 1 review

Surgical interventions for the rheumatoid shoulder 2010 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Health‐related quality of life · type 2 diabetes mellitus

The review found no eligible studies for this question.

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Health‐related quality of life · patients with type 2 diabetes mellitus

The review found no eligible studies for this question.

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Quality of life (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…

1 finding from 1 review

Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated… 2024 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 431 participants
Very low

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone

Quality of Life ‐ not reportedÂ · platinum‐sensitive recurrent EOC

The review found no eligible studies for this question.

1 finding from 1 review

Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy alone

Quality of Life ‐ not reportedÂ · recurrent platinum‐resistant EOC

The review found no eligible studies for this question.

1 finding from 1 review

Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo

Quality of life EORTC QLQ‐BN 20 · people with a primary brain tumour

1 finding from 1 review

Interventions for the management of fatigue in adults with a primary brain tumour 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Very low

Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention

Disease‐related quality of life · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Palmitoylethanolamide and luteolin vs no intervention

Disease‐related quality of life · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intranasal steroid drops vs placebo

Disease‐related quality of life · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intranasal steroid spray vs placebo or no intervention

Disease‐related quality of life · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sunitinib vs avelumab + axitinib (targeted agent versus immunotherapy + targeted agent)

Health‐related quality of life4 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

The review found no eligible studies for this question.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sunitinib vs pembrolizumab + axitinib (targeted agent versus immunotherapy + targeted agent)

Health‐related quality of life4 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

The review found no eligible studies for this question.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sunitinib vs IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted agent)

Health‐related quality of life6 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

The review found no eligible studies for this question.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sorafenib vs sunitinib (targeted agent versus targeted agent)

Health‐related quality of life5 · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

The review found no eligible studies for this question.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bevacizumab + IFN vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)

Health‐related quality of life3 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

The review found no eligible studies for this question.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Temsirolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)

Health‐related quality of life3 · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

The review found no eligible studies for this question.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Everolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)

Health‐related quality of life5 · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

The review found no eligible studies for this question.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found